Galmed Pharmaceuticals Ltd. Stock News

TEL AVIV, Israel, Dec. 17, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory

Baidu, one of China's major internet/AI companies, is talking with investors about raising $2 billion to fund a new China drug development and diagnostics company.

Recently announced Q2'20 financial results and provided key updates on development timelines. Filed IND for VK0214 in X-ALD.

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases provides today updated information on

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, curre

This article will reflect on the compensation paid to Allen Baharaff who has served as CEO of Galmed Pharmaceuticals...

On Wall Street, some things never change. Public health crisis or not, the fact of the matter remains that healthcare stocks are the epitome of risk/reward plays. Why? It comes down to the nature of t

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile market

Inventiva SA has filed to raise $90 million in a U.S. IPO. The firm is advancing a pipeline of treatment candidates for NASH, MPS and other diseases. IVA is pre

Galmed (GLMD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.